Leukemia vaccine cuts death risk 41% in phase 3 trial, drugmaker says
Sellas Life Sciences said on Tuesday that its experimental vaccine galinpepimut-S reduced the risk of death by 41% in a late-stage trial in patients with acute myeloid leukemia, a result that has not yet been peer reviewed.

The company announced topline results from the phase 3 REGAL trial, which enrolled 126 patients. It said the vaccine met the study's main goal of improving overall survival with a statistically significant margin.
Participants had acute myeloid leukemia (AML) and were in second or later remission but could not undergo a stem cell transplant. The vaccine, known as GPS, was given as maintenance therapy and compared with the best available treatment.
The data come from the company and have not been published in a journal. Sellas has not yet released results on relapse-free survival, measurable residual disease or how long the benefit lasts, according to coverage of the announcement. The trial is small, and independent experts have not yet assessed the figures.
Sellas said it plans to seek approval from the U.S. Food and Drug Administration. Its share price rose sharply after the announcement.
AML is an aggressive blood cancer, and patients who relapse after initial treatment have limited options. The Washington Post described the result as part of a broader run of positive cancer-drug trial readouts this year.



